Page 32 - GB-RI-PierreFabre-Complet-INTERACTIF

30 INTEGRATED ANNUAL REPORT 2021 - PIERRE FABRE COMPLEMENT2ARY ACTIVITIES MEDICAL CARE Ambition: BECOME AN INTERNATIONAL BIOPHARMACEUTICAL GROUP OFFERING • hope for patients with unmet medical needs, by developing promising treatments in the fields of oncology, dermatology and rare diseases • A comprehensive range of daily care and well-being products, thanks to a mature product catalog Key figures for 2020: • Revenue: €984m • 59% of sales generated internationally • R&D expenditure for oncology: 15% of oncology revenues Strategy: • Successfully launch our innovative oncology therapies for the benefit of patients • Expand our oncology research capacity, especially for immuno-oncology • Support our growth strategy, through internal research and license agreements on targeted products • Ensure the longevity of our mature product portfolio Top 10 medical franchises • Permixon, • Tardyferon, • Cyclo 3 • Braftovi&Mektovi®, • Braftovi®, • Nerlynx®, • Curacné, • Dexeryl, • Hemangiol, • Naturactive DERMO-COSMETICS & PERSONAL CARE Ambition: OFFER THE FAIREST AND MOST INNOVATIVE SOLUTIONS FOR SKIN, HAIR AND ORAL CARE, IN SUPPORT OF DAILY WELL-BEING AND BEAUTY Key figures for 2020: • Revenue: €1,216m • 68 % of sales generated internationally • R&D budget: 4% in 2020 Strategy: • Complementary brand portfolio for improving the daily lives of patients and consumers • Products manufactured to the same ethical and scientific standards as medicines • Environmentally-friendly products with 60% of new releases in 2020 compliant with the Conscious Care program • Development of an omnichannel approach and increased digital sales accounting for more than 16% of revenue in 2020 A PORTFOLIO of 8 complementary active ingredients • EAU THERMALE AVÈNE • A-DERMA • DUCRAY • KLORANE • RENÉ FURTERER • PIERRE FABRE ORAL CARE (Elgydium, Arthrodont, Inava, etc.) • GLYTONE (USA) • DARROW (Brazil)